Sanuwave Q3 Revenue Slumps 24% as CMS Rule Freezes System Sales

Sanuwave Health, Inc. (NASDAQ: SNWV) reported third-quarter 2026 revenue of $8.6 million on November 10, 2026, a 24% decline from $11.3 million in the same quarter a year earlier. The Eden Prairie, Minnesota-based wound care company swung to a GAAP operating loss of $1.1 million from operating income of $0.9 million in Q3 2025, while net loss reached $1.4 million versus net income of $9.7 million a year prior. Adjusted EBITDA fell to $0.7 million from $3.2 million. The company said the quarter was shaped by a proposed CMS rule affecting skin substitute pricing and the 97610 procedure code.

Context — Why Sanuwave's Q3 Miss Matters Now

Sanuwave's revenue decline traces to a single catalyst the company named directly. CEO Morgan Frank said Q3 "was very much the story of the CMS proposed rule," which proposed holding skin substitute pricing at 2026 levels into 2027.

The company said that proposal pushed a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations. That removed customers from Sanuwave's base.

Separately, proposed changes to the 97610 code led the market to adopt what the company described as a wait-and-see approach across the quarter. That stance, combined with an ongoing market for used Ultramist units, weighed heavily on new system sales.

The company flagged two silver linings inside the same proposal: a 14% increase in hospital outpatient department rates for 97610, and removal of Q1 status from the code. That status change would allow 97610 to be billed alongside other procedures rather than packaged to zero.

Sanuwave said CMS and the American Medical Association RUC have both signaled interest in reviewing the structure of the 97610 code, including scaling factors for multiple, large, or difficult wounds common in other wound care codes.

Data — What the Numbers Show

The sharpest figure in the release is system placements. Sanuwave sold 40 Ultramist systems in Q3 2026, down from 155 in Q3 2025 and from 82 in Q2 2026. That is a 74% year-over-year decline and a 51% sequential decline.

Applicator revenue, the recurring consumable line, moved the other way. Ultramist applicator revenue rose 2% to $6.9 million from $6.8 million a year earlier.

Gross margin held nearly flat at 77.3% versus 77.6%. Operating expenses were $7.7 million against $7.8 million a year prior.

Metric	Q3 2026	Q3 2025	Change
Revenue	$8.6M	$11.3M	-24%
Gross margin %	77.3%	77.6%	-30 bps
Operating income (loss)	$(1.1)M	$0.9M	Swing
Net income (loss)	$(1.4)M	$9.7M	Swing
Adjusted EBITDA	$0.7M	$3.2M	-78%
Ultramist systems sold	40	155	-74%

Nine-month revenue was $27.9 million versus $30.7 million, a 9% decline. Nine-month gross margin was 76.9% versus 78.2%.

The prior-year quarter's net income included a $6.1 million non-cash gain on derivative liabilities and a one-time $5.0 million gain on the sale of patents, neither of which recurred. Interest expense fell $1.5 million year over year, partially offsetting the operating swing.

Cash and cash equivalents stood at $6.6 million on September 30, 2026, down from $11.9 million at December 31, 2025. The company said roughly $2.3 million went out under sales tax voluntary disclosure agreements during the quarter.

Analysis — What It Means for Markets and Sectors

The split between system sales and applicator revenue is the number that matters for anyone modeling Sanuwave. Applicators are the recurring consumable tied to an installed base; systems are the capital purchase that expands that base. A 74% drop in placements with flat applicator revenue means the installed base is still generating revenue, but the pipeline that feeds future consumable growth has narrowed sharply.

That exposes the company to a simple arithmetic problem. If placements stay near 40 per quarter, the consumable base stops growing and eventually decays as units retire. The company pointed to hospitals as the offset, saying it continues to gain traction where cost savings from halting wound progression is the primary concern.

Reimbursement policy is the dominant risk here, not competition or demand. The company's own account attributes the shortfall to a proposed rule and to customer exits, not to lost share. That distinction matters: a policy-driven pause can reverse if the final rule lands favorably, while share loss usually does not.

The counter-argument is that the used-Ultramist market the company acknowledged suggests some of the softness is structural. Buyers substituting used units for new ones would suppress placements even after policy clarity returns.

Positioning is difficult to read from the release alone. The company did not disclose short interest, institutional holdings, or any guidance figure for Q4 2026. It also did not disclose the terms of its secured revolving credit facility, which carried $655,000 drawn at September 30, 2026, against none at December 31, 2025.

Outlook — What to Watch Next

Sanuwave scheduled a business update conference call for November 11, 2026 at 8:30 a.m. EST, with materials posted to its investor site. That call is the next scheduled disclosure event.

The company did not provide revenue or earnings guidance for the fourth quarter or full-year 2026, so the call and any subsequent filings are the only stated checkpoints.

The central catalyst is the final CMS rule on skin substitute pricing and the 97610 code. The company said it will seek to encourage and engage with CMS and the AMA RUC review of the code's structure. A finalized 14% HOPD rate increase and removal of Q1 status are the specific items the company identified as favorable.

Investors watching the placement trend will want to see whether Q4 system sales recover from the 40-unit level, or whether the used-equipment market keeps absorbing demand. The company's cash position, reduced by the sales tax payouts, is the other line to track given the $5.7 million current portion of its secured term loan.

Frequently Asked Questions

What does Sanuwave's Q3 2026 revenue decline mean for retail investors?

Revenue fell 24% year over year to $8.6 million, driven by a 74% drop in Ultramist system placements. The recurring applicator line grew 2%, so the installed base is still producing revenue. The key question for retail holders is whether placements recover once CMS finalizes its skin substitute pricing rule, or whether used-equipment demand permanently caps new unit sales.

Why did Sanuwave's net income swing from $9.7 million profit to a $1.4 million loss?

The prior-year quarter included two non-recurring items: a $6.1 million non-cash gain on the change in fair value of derivative liabilities and a $5.0 million gain on the sale of patents. Neither recurred in Q3 2026. The current quarter also carried a $1.1 million operating loss versus $0.9 million of operating income a year earlier, partly offset by $1.5 million lower interest expense.

What happens next for Sanuwave and the 97610 code?

Sanuwave said CMS proposed a 14% increase in hospital outpatient department rates for 97610 and removal of its Q1 status, which would let it be billed alongside other procedures instead of packaged to zero. CMS and the AMA RUC have signaled interest in reviewing the code's scaling factors. The company said it will engage with that process.

Bottom Line

Sanuwave's consumable base held flat while system sales collapsed on a proposed CMS rule the company says drove customers to the sidelines.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.